Siemens Medical Solutions USA, Inc.

Westfaelische Wilhelms-Universitaet Muenster

Merck Patent Gmbh

Guenter Haufe

Peer Kirsch

Michael Schaefers

Joseph C Walsh

Gang Chen

Umesh B Gangadharmath

Dhanalakshmi Kasi

Eric Wang

Anna Katrin Szardenings

Anjana Sinha

Changhui Liu

Chul Yu

Sven Hermann

Andreas Faust

Bodo Levkau

Stefani Silke Schilson

Petra Keul

Harmuth C Kolb

Klaus Kopka

Verena Hugenberg

Stefan Wagner

Hans-Joerg Breyholz

Volodymyr Kozel

Jakub Grajewski

The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogs, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.

Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof

Growing community of inventors

Muenster, Germany

Guenter Haufe